GHD is a dubious disease in the field of genetic metabolism, clinical performance is complex and often involves multiple systemic strain. Early identification and standardised clinical care are essential for improving prognosis. Diagnosis of the disease requires a combination of clinical performance, imaging, laboratory testing and pathology.
The platform can help align teams of authoritative experts at home and abroad to provide accurate diagnosis and treatment programs. Treatment and management of GHD requires individualized management, typically including drug therapy, rehabilitation, regular follow-up, and other multidimensional management. In recent years, with the development of therapeutic, immune-regulatory therapy and precision medicine, significant improvements have been made in many previously difficult-to-treat genetic metabolic disorders.
Treatment needs to be closely monitored for efficacy and adverse reactions, adapted to timely scheduling according to changes in the disease. Multidisciplinary collaboration (MDT) is particularly important for the comprehensive management of growth hormone deficiency IHD. The platform serves a team of domestic and foreign experts in the field of genetic metabolism linked to the China International Medical Service System, providing the following services to patients: 1.
2. Visiting China: arranging face-to-face treatment with authoritative experts, developing individualized treatment plans; 3. Full-service: providing one-stop services such as medical translation, medical care, accommodation arrangements; 4.
Long-term follow-up: establishing a chronic disease management archive, continuous monitoring of disease changes and treatment effects.